

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:

Symbol(s):

XPhyto Therapeutics Corp. (the "Issuer").	XPHY
---	------

Date: January 31, 2020

Is this an updating or amending Notice: ☐ Yes ☒ No

If yes provide date(s) of prior Notices: _____

Issued and Outstanding Securities of Issuer Prior to Issuance: 50,756,269

Pricing

Date of news release announcing proposed issuance: January 27, 2020 or

Date of confidential request for price protection: January 9, 2020

Closing Market Price on Day Preceding the news release: \$1.45 or

Day preceding request for price protection: \$1.00

Closing

Number of securities to be issued: 2,000 Debentures Unit for aggregate gross proceeds of \$2,000,000, which may be issued in two or more tranches

Issued and outstanding securities following issuance: 50,756,269

Part 1. Private Placement

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
To be determined			
Total dollar value of distribution in all jurisdictions:			

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date (1)	Describe relationship to Issuer (2)
N/A							

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised:

Up to \$2,000,000, which may be raised through the closing of two or more tranches

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

The Issuer intends to use the proceeds from the private placement to facilitate European imports by way of expanded EU GMP lab processing and storage capacity, associated regulatory compliance, and product development and manufacturing, as well as general working capital.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer:

Not applicable

4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.

Not applicable

5. Description of securities to be issued:

(a) Class: Debenture Units. Each Debenture Unit is comprised of (i) \$1,000 principal amount of unsecured convertible debenture of the Issuer and (ii) 1,000 common share purchase warrants

(b) Number: 2,000 Debenture Units, which may be issued in two or more tranches

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

September 2018
Page 2

- (c) Price per security: \$1,000 per Debenture Unit
- (d) Voting rights: None
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
- (a) Number 2,000,000
- (a) Number of securities eligible to be purchased on exercise of warrants (or options) Up to 2,000,000
- (c) Exercise price \$1.50
- (d) Expiry date two years from date of issuance
7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount: \$2,000,000 Debentures
- (b) Maturity date: two years from date of issuance
- (c) Interest rate: 8% per annum, calculated and payable semi-annually
- (d) Conversion terms:
- The Debentures are convertible into Common Shares at the option of the holder at any time prior to the close of business on the Maturity Date to convert all or any portion of the outstanding Principal Amount at \$1.00 per share (the "Conversion Price").
- Subject to the Debentureholder's conversion rights, the Issuer may elect to force settlement of the Principal Amount if the 15-day volume weighted average price of the Common Shares of the Issuer on the CSE or any other stock exchange which serves as the principal stock exchange for the Issuer exceeds \$2.50 per share.
- (e) Default provisions: The breach of US cannabis laws, non-compliance with the terms of the Debentures, breaches of representations and warranties, and customary provisions relating to the continuation of the business
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

September 2018
Page 3

corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):

Canaccord Genuity Corp. – 2200 – 609 Granville St., Vancouver, BC
V7Y 1H2

- (b) Cash: \$120,000.
- (c) Securities: Finder's Warrants exercisable into 120,000 common shares at \$1.00 per share
- (d) Other: N/A
- (e) Expiry date of any options, warrants etc.: two years from date of issuance
- (f) Exercise price of any options, warrants etc.: \$1.00

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship:

Not applicable

10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.):

Not applicable

11. State whether the private placement will result in a change of control.

No

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Not applicable

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities. Confirmed.

Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

The Issuer entered into a strategic partnership and supply agreement (the “**Agreement**”) dated January 13, 2020 with PharmaCielo Ltd. (“**Pharmacielo**”), a company engaged in the business of cultivation and supply of medical-grade cannabis oil extracts and related products (the “**Products**”), pursuant to which the Issuer will purchase Products from PharmaCielo and act as distributor of the Products in certain territories. .

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

Please refer to Item 1.

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

(a) Total aggregate consideration in Canadian dollars: N/A .

(b) Cash: The Issuer will purchase the Products from PharmaCielo at the prices as set out in the Agreement .

(c) Securities (including options, warrants etc.) and dollar value: 500,000 common share purchase warrants .

(d) Other: N/A .

(e) Expiry date of options, warrants, etc. if any: two years from date of issuance .

(f) Exercise price of options, warrants, etc. if any: \$2.00 .

(g) Work commitments: Not applicable .

3. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

Arm's length negotiation .

4. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: Not applicable.
5. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾
PharmaCielo Ltd.	500,000 Warrants	N/A	\$2.00	Section 2.3 of NI 45-106	N/A	N/A

(1) Indicate if Related Person

6. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: The Issuer intends to rely on the representations and warranties in the Agreement.
7. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): Not applicable
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A.
- (b) Cash Not applicable.
- (c) Securities Not applicable.
- (d) Other Not applicable.
- (e) Expiry date of any options, warrants etc. Not applicable.
- (f) Exercise price of any options, warrants etc. Not applicable.
8. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. Not applicable

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

September 2018
Page 6

9. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. Not applicable

_____ .

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated January 31, 2020

Hugh Rogers
Name of Director or Senior
Officer

"Hugh Rogers"
Signature

Chief Executive Officer
Official Capacity

Appendix A

PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, "CSE or the "Exchange") collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

-
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange's obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.